BCL2 and neoplasm: These findings also suggest that it might be possible to use expression of Bcl-2 as a molecular marker to predict the patient prognosis when the information on tumor stage (TNM) is not available; specifically, useful in assessing the aggressiveness of the tumor at the time of biopsy.